Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2021, Vol. 50 Issue (6): 685-693    DOI: 10.3724/zdxbyxb-2021-0249
专题报道     
甲状腺未分化癌靶向治疗研究进展
钱晨宏1,2,蒋烈浩2,3,许世莹2,4,王佳峰2,3,谭卓2,3,忻莹2,3,葛明华1,2,3,*()
1.蚌埠医学院研究生院，安徽 蚌埠 233030
2.杭州医学院附属人民医院 浙江省人民医院耳鼻咽喉-头颈外科中心头颈外科， 浙江 杭州 310014
3.浙江省内分泌腺体疾病诊治研究重点实验室，浙江 杭州 310014
4.浙江中医药大学第二临床医学院，浙江 杭州 310053
Advances in targeted therapy for anaplastic thyroid carcinoma
QIAN Chenhong1,2,JIANG Liehao2,3,XU Shiying2,4,WANG Jiafeng2,3,TAN Zhuo2,3,XIN Ying2,3,GE Minghua1,2,3,*()
1. Graduate School, Bengbu Medical College, Bengbu 233030, Anhui Province, China;
2. Department of Head and Neck Surgery, Center of Otolaryngology, Head and Neck Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital of Hangzhou Medical College, Hangzhou 310014, China;
3. Zhejiang Provincial Key Laboratory of Endocrine Gland Diseases, Hangzhou 310014, China;
4. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China
 全文: PDF(2401 KB)   HTML( 22 )
摘要：

甲状腺未分化癌（ATC）是一种恶性程度高、侵袭性强的甲状腺恶性肿瘤，发病迅速，预后差，目前尚缺乏有效治疗手段。分子靶向治疗为ATC治疗提供了一种新思路。酪氨酸激酶抑制剂乐伐替尼在治疗ATC患者临床试验中疗效良好；鼠类肉瘤病毒癌基因同源物B1（BRAF）基因抑制剂达拉非尼联合曲美替尼治疗BRAFV600E阳性ATC患者的有效性已在临床试验中得到证实，2021年美国国家综合癌症网络甲状腺癌临床实践指南中提出达拉非尼联合曲美替尼可作为治疗BRAFV600E阳性ATC患者治疗的首选方式；免疫检查点抑制剂帕博利珠单抗应用于高肿瘤突变负荷甲状腺癌治疗，可作为程序性死亡蛋白1高表达ATC患者的首选方式；哺乳动物雷帕霉素靶蛋白通路抑制剂、过氧化物酶体增殖物激活受体γ激动剂、靶向内皮生长因子受体的单克隆抗体西妥昔单抗及新型血管阻断剂康布瑞汀磷酸二钠仍处于临床研究阶段。本文综述了目前ATC靶向药物治疗的研究进展。
关键词： 甲状腺未分化癌;  靶向治疗;  免疫治疗;  临床治疗;  综述    
Abstract:

Anaplastic thyroid carcinoma (ATC) is a highly malignant and aggressive thyroid malignancy with rapid onset and poor prognosis. There is no effective treatment for ATC yet. Molecular targeted therapy provides a new idea for ATC treatment. Tyrosine kinase inhibitor lenvatinib has potential in treating ATC patients with favorable efficacy in clinical trials. The effectiveness of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) gene inhibitor dabrafenib in combination with trametinib for the treatment of BRAFV600E positive ATC patients has been demonstrated in clinical trials. The NCCN clinical practice guidelines in oncology has proposed dabrafenib in combination with trametinib as the preferred modality for the treatment of patients with BRAFV600E positive ATC. The immune checkpoint inhibitor pembrolizumab can be applied to treat thyroid cancer with high tumor mutational load and may be considered as the preferred modality for the treatment of ATC patients with high programmed death ligand-1 expression. The mammalian target of rapamycin pathway inhibitors, peroxisome proliferators-activated receptor γ agonists, endothelial growth factor receptors-targeting monoclonal antibody cetuximab and novel vascular blocker fosbretabulin are still in the clinical research stage, which are expected to provide new directions for the development of novel targeted drugs. This article reviews the current research progress on targeted drugs for the treatment of ATC.
Key words: Anaplastic thyroid carcinoma    Targeted therapy    Immunotherapy    Clinical treatment    Review
收稿日期: 2021-08-25 出版日期: 2022-03-22
CLC:  R736.1  
基金资助: 国家自然科学基金（81872170）；区域创新发展联合基金（U20A20382）；浙江省医学会临床科研基金（2017ZYC-A03）
通讯作者: 葛明华     E-mail: geminghua@hmc.edu.cn
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
钱晨宏
蒋烈浩
许世莹
王佳峰
谭卓
忻莹
葛明华

引用本文:

钱晨宏,蒋烈浩,许世莹,王佳峰,谭卓,忻莹,葛明华. 甲状腺未分化癌靶向治疗研究进展[J]. 浙江大学学报（医学版）, 2021, 50(6): 685-693.

QIAN Chenhong,JIANG Liehao,XU Shiying,WANG Jiafeng,TAN Zhuo,XIN Ying,GE Minghua. Advances in targeted therapy for anaplastic thyroid carcinoma. J Zhejiang Univ (Med Sci), 2021, 50(6): 685-693.

链接本文:

https://www.zjujournals.com/med/CN/10.3724/zdxbyxb-2021-0249    或    https://www.zjujournals.com/med/CN/Y2021/V50/I6/685

1 CHINTAKUNTLAWARA V, FOOTER L, KASPERBAUERJ L, et al.Diagnosis and management of anaplastic thyroid cancer[J]Endocrinol Metab Clin N Am, 2019, 48( 1): 269-284.
doi: 10.1016/j.ecl.2018.10.010
2 SPARTALISE, ATHANASIADISD I, CHRYSIKOSD, et al.Histone deacetylase inhibitors and anaplastic thyroid carcinoma[J]Anticancer Res, 2019, 39( 3): 1119-1127.
doi: 10.21873/anticanres.13220
3 NCCN. NCCN clinical practice guidelines in oncology: thyroid carcinoma[EB/OL]. [2021-04-09]. http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf
4 TADESSEF, ASRESG, ABUBEKERA, et al.Spectrum of bcr-abl mutations and treatment outcomes in ethiopian imatinib-resistant patients with chronic myeloid leukemia[J]JCO Glob Oncol, 2021, 1187-1193.
doi: 10.1200/GO.21.00058
5 RIUDAVETSM, BOSCH-BARRERAJ, CABEZóN-GUTIéRREZL, et al.Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma[J]Clin Transl Oncol, 2021, 23( 12): 2560-2567.
doi: 10.1007/s12094-021-02661-2
6 PERRIF, PEZZULLOL, CHIOFALOM G, et al.Targeted therapy: a new hope for thyroid carcinomas[J]Crit Rev Oncol Hematology, 2015, 94( 1): 55-63.
doi: 10.1016/j.critrevonc.2014.10.012
7 ISHIHARAS, ONODAN, NODAS, et al.Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status[J]Int J Oncol, 2019, 55( 5): 1069-1076.
doi: 10.3892/ijo.2019.4881
8 SAVVIDESP, NAGAIAHG, LAVERTUP, et al.Phase Ⅱ trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J]Thyroid, 2013, 23( 5): 600-604.
doi: 10.1089/thy.2012.0103
9 ITOY, ONODAN, ITOK I, et al.Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma[J]Thyroid, 2017, 27( 9): 1142-1148.
doi: 10.1089/thy.2016.0621
10 KIMS Y, KIMS M, CHANGH, et al.Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo[J]Head Neck, 2020, 42( 12): 3678-3684.
doi: 10.1002/hed.26431
11 YUNH J, KIMH J, KIMJ, et al.Synergistic anticancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide, sorafenib, and radiation therapy in patient-derived anaplastic thyroid cancer models[J]Int J Mol Sci, 2021, 22( 2): 536.
doi: 10.3390/ijms22020536
12 HAOZ, WANGP. Lenvatinib in management of solid tumors[J/OL]Oncologist, 2020, 25( 2): e302-e310.
doi: 10.1634/theoncologist.2019-0407
13 TAKAHASHIS, KIYOTAN, YAMAZAKIT, et al.A-phase Ⅱ study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer[J]Future Oncol, 2019, 15( 7): 717-726.
doi: 10.2217/fon-2018-0557
14 KIMS Y, KIMS M, KIMJ W, et al.Survival with lenvatinib for the treatment of progressive anaplastic thyroid cancer: a single-center, retrospective analysis[J]Front Endocrinol, 2020, 599.
doi: 10.3389/fendo.2020.00599
15 BARBAROD, LAPIP, VIACAVAP, et al.Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe[J/OL]BMJ Case Rep, 2020, 13( 12): e236934.
doi: 10.1136/bcr-2020-236934
16 RUANX, SHIX, DONGQ, et al.Antitumor effects of anlotinib in thyroid cancer[J]Endocrine-Relat Cancer, 2019, 26( 1): 153-164.
doi: 10.1530/ERC-17-0558
17 GUIL, LIUS, ZHANGY, et al.A remarkable and durable response to sintilimab and anlotinib in the first-line treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report[J]Onco Targets Ther, 2021, 2741-2746.
doi: 10.2147/OTT.S305196
18 HAH T, LEEJ S, URBAS, et al.A phase Ⅱ study of imatinib in patients with advanced anaplastic thyroid cancer[J]Thyroid, 2010, 20( 9): 975-980.
doi: 10.1089/thy.2010.0057
19 PALMBERGE, JOHNSENJ I, PAULSSONJ, et al.Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo[J]Int J Cancer, 2009, 124( 5): 1227-1234.
doi: 10.1002/ijc.24069
20 WESTEKEMPERH, FREISTUEHLERM, ANASTASSIOUG, et al.Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations[J]Br J Ophthalmol, 2012, 96( 4): 591-596.
doi: 10.1136/bjophthalmol-2011-300686
21 KIME S, MATSUSEM, SAENKOV, et al.Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-κB activation in anaplastic thyroid carcinoma cells[J]Thyroid, 2012, 22( 7): 717-724.
doi: 10.1089/thy.2011.0380
22 RAVAUDA, DE LA FOUCHARDIèREC, CARONP, et al.A multicenter phase Ⅱ study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study[J]Eur J Cancer, 2017, 110-117.
doi: 10.1016/j.ejca.2017.01.029
23 BIBLEK C, SUMANV J, MENEFEEM E, et al.A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer[J]J Clin Endocrinol Metab, 2012, 97( 9): 3179-3184.
doi: 10.1210/jc.2012-1520
24 ISHAMC R, BOSSOUA R, NEGRONV, et al.Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer[J]Sci Transl Med, 2013, 5( 166): 166ra3.
doi: 10.1126/scitranslmed.3004358
25 WANG L, LI W, LIU Y, et al. Clinical study on the safety, efficacy, and prognosis of molecular targeted drug therapy for advanced gastric cancer[J]. Am J Transl Res, 2021,13(5): 4704-4711
26 LIH, GENGC, ZHAOH, et al.Multicenter phase Ⅱ study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis[J]Chin J Cancer Res, 2021, 33( 2): 243-255.
doi: 10.21147/j.issn.1000-9604.2021.02.11
27 ZHAOH, YAOW, MINX, et al.Apatinib plus gefitinib as first-line treatment in advanced egfr-mutant nsclc: the phase Ⅲ active study (ctong1706)[J]J Thoracic Oncol, 2021, 16( 9): 1533-1546.
doi: 10.1016/j.jtho.2021.05.006
28 CHENGL, JIAOQ, JINY, et al.Initial therapy of advanced anaplastic thyroid cancer via targeting VEGFR-2: a case report[J]Onco Targets Ther, 2019, 10495-10500.
doi: 10.2147/OTT.S223727
29 FENGH, CHENGX, KUANGJ, et al.Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer[J]Cell Death Dis, 2018, 9( 10): 1030.
doi: 10.1038/s41419-018-1054-3
30 GULEM K, CHENY, SANOD, et al.Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model[J]Clin Cancer Res, 2011, 17( 8): 2281-2291.
doi: 10.1158/1078-0432.CCR-10-2762
31 FERRARIS M, BOCCIG, DI DESIDEROT, et al.Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo[J]Oncol Rep, 2018, 39( 5): 2306-2314.
doi: 10.3892/or.2018.6305
32 BIBLEK C, RYDERM. Evolving molecularly targeted therapies for advanced-stage thyroid cancers[J]Nat Rev Clin Oncol, 2016, 13( 7): 403-416.
doi: 10.1038/nrclinonc.2016.19
33 MASHAYEKHI-SARDOOH, HOSSEINJANIH. A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19[J]J Basic Clin Physiol Pharmacol, 2021, online,
doi: 10.1515/jbcpp-2020-0495
34 CORTADAM, LEVANOS, BODMERD. mTOR signaling in the inner ear as potential target to treat hearing loss[J]Int J Mol Sci, 2021, 22( 12): 6368.
doi: 10.3390/ijms22126368
35 SAXTONR A, SABATINID M. mTOR signaling in growth, netabolism, and disease[J]Cell, 2017, 168( 6): 960-976.
doi: 10.1016/j.cell.2017.02.004
36 JINN, JIANGT, ROSEND M, et al.Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer[J]J Clin Endocrinol Metab, 2009, 94( 10): 4107-4112.
doi: 10.1210/jc.2009-0662
37 WAGLEN, GRABINERB C, VAN ALLENE M, et al.Response and acquired resistance to everolimus in anaplastic thyroid cancer[J]N Engl J Med, 2014, 371( 15): 1426-1433.
doi: 10.1056/NEJMoa1403352
38 BERNOCCHIO, SIRICOM, CORONAS P, et al.Tumor type agnostic therapy carrying braf mutation: case reports and review of literature[J]Pharmaceuticals, 2021, 14( 2): 159.
doi: 10.3390/ph14020159
39 LIAOY, GAOY, CHANGA, et al.Melatonin synergizes BRAF‐targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling[J]J Cell Mol Med, 2020, 24( 20): 12119-12130.
doi: 10.1111/jcmm.15854
40 FERRARIS M, ELIAG, RAGUSAF, et al.Novel treatments for anaplastic thyroid carcinoma[J]Gland Surg, 2020, 9( S1): S28-S42.
doi: 10.21037/gs.2019.10.18
41 SUBBIAHV, KREITMANR J, WAINBERGZ A, et al.Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer[J]J Clin Oncol, 2018, 36( 1): 7-13.
doi: 10.1200/JCO.2017.73.6785
42 WANGJ R, ZAFEREOM E, DADUR, et al.Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma[J]Thyroid, 2019, 29( 8): 1036-1043.
doi: 10.1089/thy.2019.0133
43 ROSOVEM H, PEDDIP F, GLASPYJ A. BRAF V600E inhibition in anaplastic thyroid cancer[J]N Engl J Med, 2013, 368( 7): 684-685.
doi: 10.1056/NEJMc1215697
44 PILLIT, CANTARAS, MARZOCCHIC, et al.Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells[J]Endocrine, 2020, 67( 1): 117-123.
doi: 10.1007/s12020-019-02028-2
45 GRECEAM, SORITAUO, DULFD, et al.Potential biomarkers for the efficacy of PD-1-PD-L blockade in cancer[J]Onco Targets Ther, 2021, 5275-5291.
doi: 10.2147/OTT.S283892
46 ADAMP, KIRCHERS, SBIERAI, et al.FGF-receptors and PD-L1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale[J]Front Endocrinol, 2021, 12, 712107.
doi: 10.3389/fendo.2021.712107
47 AHNS, KIMT H, KIMS W, et al.Comprehensive screening for PD-L1 expression in thyroid cancer[J]Endocrine-Relat Cancer, 2017, 24( 2): 97-106.
doi: 10.1530/ERC-16-0421
48 AGHAJANIM J, COOPERA, MCGUIREH, et al.Pembrolizumab for anaplastic thyroid cancer: a casestudy[J]Cancer Immunol Immunother, 2019, 68( 12): 1921-1934.
doi: 10.1007/s00262-019-02416-7
49 DIERKSC, SEUFERTJ, AUMANNK, et al.Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma[J]Thyroid, 2021, 31( 7): 1076-1085.
doi: 10.1089/thy.2020.0322
50 KOLLIPARAR, SCHNEIDERB, RADOVICHM, et al.Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer[J]Oncologist, 2017, 22( 10): 1149-1151.
doi: 10.1634/theoncologist.2017-0096
51 PRICHARDC N, KIMS, YAZICIY D, et al.Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma[J]Laryngoscope, 2007, 117( 4): 674-679.
doi: 10.1097/MLG.0b013e318031055e
52 KIMS, PRICHARDC N, YOUNESM N, et al.Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]Clin Cancer Res, 2006, 12( 2): 600-607.
doi: 10.1158/1078-0432.CCR-05-1325
53 SMALLRIDGER C, COPLANDJ A, BROSEM S, et al.Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial[J]J Clin Endocrinol Metab, 2013, 98( 6): 2392-2400.
doi: 10.1210/jc.2013-1106
54 DZIBAJ M, MARCINEKR, VENKATARAMANG, et al.Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors[J]Thyroid, 2002, 12( 12): 1063-1070.
doi: 10.1089/105072502321085153
55 MOONEYC J, NAGAIAHG, FUP, et al.A phase Ⅱ trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome[J]Thyroid, 2009, 19( 3): 233-240.
doi: 10.1089/thy.2008.0321
[1] 卢茜璇,包黎莎,潘宗富,葛明华. 甲状腺未分化癌免疫治疗的现状及未来[J]. 浙江大学学报（医学版）, 2021, 50(6): 675-684.
[2] 马丽娟,吴爽,张凯,田梅,张宏. 大麻素1型受体正电子发射断层显像在神经精神疾病中的应用进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 666-673.
[3] 宣自学,张轶雯,潘宗富,郑小卫,黄萍. 天然药物成分干预铁死亡抑制肿瘤的作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 601-606.
[4] 曲文政,庄英粮,李学坤. 表观遗传修饰在神经退行性变性疾病中的作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 642-650.
[5] 孙琦,曹蔚,罗建红. 含GluN3亚基的N-甲基-D-天冬氨酸受体及其在中枢神经系统的功能[J]. 浙江大学学报（医学版）, 2021, 50(5): 651-658.
[6] 史建蓉,马望前,汤慧芳. 磷酸二酯酶抑制剂治疗炎性肠病的研究进展[J]. 浙江大学学报（医学版）, 2021, 50(5): 659-665.
[7] 唐玥,孔元原. 遗传性酪氨酸血症Ⅰ型及其筛查和诊治进展[J]. 浙江大学学报（医学版）, 2021, 50(4): 514-523.
[8] 刘飞,冯春月,毛建华,傅海东. 2019冠状病毒病疫苗接种相关新发及复发肾小球病研究进展[J]. 浙江大学学报（医学版）, 2021, 50(4): 524-528.
[9] 韩连书. 新生儿遗传病基因筛查技术及相关疾病[J]. 浙江大学学报（医学版）, 2021, 50(4): 429-435.
[10] 胡茫莎,韦树丽,周武源,王苹莉. 新生儿Fc受体基础研究和临床应用进展[J]. 浙江大学学报（医学版）, 2021, 50(4): 537-544.
[11] 胡靖依,王青青,刘杨. 蛋白酶体亚基对肝细胞癌发生发展的调控作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(3): 396-402.
[12] 葛瀛洲,刘欣梅,黄荷凤. 沉默信息调节因子家族参与病理妊娠的研究进展[J]. 浙江大学学报（医学版）, 2021, 50(3): 335-344.
[13] 王锦涛,黄蕾,魏丽丽,陈炜. 重复经颅磁刺激治疗阿尔茨海默病患者的疗效影响因素[J]. 浙江大学学报（医学版）, 2021, 50(3): 383-389.
[14] 庄文雯,杨咏琪,李洪亮,梁景岩. 动脉粥样硬化过程中核因子E2相关因子2对血管平滑肌细胞的调控作用[J]. 浙江大学学报（医学版）, 2021, 50(3): 390-395.
[15] 朱锋,项迎春,曾玲晖. 线粒体沉默信息调节因子家族在癫痫发生发展中的作用研究进展[J]. 浙江大学学报（医学版）, 2021, 50(3): 403-408.